Natural variability in the disease course of SSc-ILD: implications for treatment
Interstitial lung disease (ILD) affects approximately 50% of patients with systemic sclerosis (SSc) and is the leading cause of death in SSc. Our objective was to gain insight into the progression of SSc-associated ILD (SSc-ILD). Using data from longitudinal clinical trials and observational studies...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
March 24, 2021
|
| In: |
European respiratory review
Year: 2021, Jahrgang: 30, Heft: 159, Pages: 1-14 |
| ISSN: | 1600-0617 |
| DOI: | 10.1183/16000617.0340-2020 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1183/16000617.0340-2020 Verlag, lizenzpflichtig, Volltext: https://err.ersjournals.com/content/30/159/200340 
|
| Verfasserangaben: | Madelon C. Vonk, Ulrich A. Walker, Elizabeth R. Volkmann, Michael Kreuter, Sindhu R. Johnson and Yannick Allanore |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1762541327 | ||
| 003 | DE-627 | ||
| 005 | 20220820013510.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210709s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1183/16000617.0340-2020 |2 doi | |
| 035 | |a (DE-627)1762541327 | ||
| 035 | |a (DE-599)KXP1762541327 | ||
| 035 | |a (OCoLC)1341418280 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Vonk, Madelon C. |e VerfasserIn |0 (DE-588)1236760336 |0 (DE-627)1762541971 |4 aut | |
| 245 | 1 | 0 | |a Natural variability in the disease course of SSc-ILD |b implications for treatment |c Madelon C. Vonk, Ulrich A. Walker, Elizabeth R. Volkmann, Michael Kreuter, Sindhu R. Johnson and Yannick Allanore |
| 264 | 1 | |c March 24, 2021 | |
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 09.07.2021 | ||
| 520 | |a Interstitial lung disease (ILD) affects approximately 50% of patients with systemic sclerosis (SSc) and is the leading cause of death in SSc. Our objective was to gain insight into the progression of SSc-associated ILD (SSc-ILD). Using data from longitudinal clinical trials and observational studies, we assessed definitions and patterns of progression, risk factors for progression, and implications for treatment. </p><p>SSc-ILD progression was commonly defined as exceeding specific thresholds of lung function worsening and/or increasing radiographic involvement. One definition used in several studies is decline in forced vital capacity (FVC) of ≥10%, or ≥5-10% plus a decline in diffusing capacity of the lung for carbon monoxide ≥15%. Based on these criteria, 20-30% of patients in observational cohorts develop progressive ILD, starting early in the disease course and progressing at a highly variable rate.</p><p>Risk factors such as age, FVC, extent of fibrosis and presence of anti-topoisomerase I antibodies can help predict progression of SSc-ILD, though composite risk scores may offer greater predictive power. Whilst the variability of the disease course in SSc-ILD makes risk stratification of patients challenging, the decision to initiate, change or stop treatment should be based on a combination of the current disease state and the speed of progression. | ||
| 700 | 1 | |a Walker, Ulrich A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Volkmann, Elizabeth R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kreuter, Michael |d 1972- |e VerfasserIn |0 (DE-588)122645995 |0 (DE-627)082066795 |0 (DE-576)293362742 |4 aut | |
| 700 | 1 | |a Johnson, Sindhu R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Allanore, Yannick |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European respiratory review |d Sheffield : Soc., 2005 |g 30(2021), 159, Artikel-ID 200340, Seite 1-14 |h Online-Ressource |w (DE-627)500021430 |w (DE-600)2202947-3 |w (DE-576)281286477 |x 1600-0617 |7 nnas |a Natural variability in the disease course of SSc-ILD implications for treatment |
| 773 | 1 | 8 | |g volume:30 |g year:2021 |g number:159 |g elocationid:200340 |g pages:1-14 |g extent:14 |a Natural variability in the disease course of SSc-ILD implications for treatment |
| 856 | 4 | 0 | |u https://doi.org/10.1183/16000617.0340-2020 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://err.ersjournals.com/content/30/159/200340 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210709 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 122645995 |a Kreuter, Michael |m 122645995:Kreuter, Michael |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PK122645995 |e 950000PK122645995 |e 950900PK122645995 |e 50000PK122645995 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 4 | ||
| 999 | |a KXP-PPN1762541327 |e 394693174X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 09.07.2021"],"recId":"1762541327","person":[{"family":"Vonk","roleDisplay":"VerfasserIn","role":"aut","given":"Madelon C.","display":"Vonk, Madelon C."},{"family":"Walker","display":"Walker, Ulrich A.","roleDisplay":"VerfasserIn","role":"aut","given":"Ulrich A."},{"display":"Volkmann, Elizabeth R.","given":"Elizabeth R.","roleDisplay":"VerfasserIn","role":"aut","family":"Volkmann"},{"display":"Kreuter, Michael","given":"Michael","role":"aut","roleDisplay":"VerfasserIn","family":"Kreuter"},{"family":"Johnson","given":"Sindhu R.","roleDisplay":"VerfasserIn","role":"aut","display":"Johnson, Sindhu R."},{"role":"aut","roleDisplay":"VerfasserIn","given":"Yannick","display":"Allanore, Yannick","family":"Allanore"}],"language":["eng"],"name":{"displayForm":["Madelon C. Vonk, Ulrich A. Walker, Elizabeth R. Volkmann, Michael Kreuter, Sindhu R. Johnson and Yannick Allanore"]},"physDesc":[{"extent":"14 S."}],"id":{"eki":["1762541327"],"doi":["10.1183/16000617.0340-2020"]},"origin":[{"dateIssuedDisp":"March 24, 2021","dateIssuedKey":"2021"}],"relHost":[{"pubHistory":["Nachgewiesen 14.2005 - ; auch mit durchgehender Nr.-Zählung"],"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 31.10.24"],"recId":"500021430","part":{"issue":"159","volume":"30","pages":"1-14","year":"2021","extent":"14","text":"30(2021), 159, Artikel-ID 200340, Seite 1-14"},"id":{"issn":["1600-0617"],"eki":["500021430"],"zdb":["2202947-3"]},"corporate":[{"roleDisplay":"Herausgebendes Organ","role":"isb","display":"European Respiratory Society"}],"physDesc":[{"extent":"Online-Ressource"}],"name":{"displayForm":["European Respiratory Society"]},"origin":[{"publisherPlace":"Sheffield","dateIssuedKey":"2005","dateIssuedDisp":"2005-","publisher":"Soc."}],"language":["eng"],"disp":"Natural variability in the disease course of SSc-ILD implications for treatmentEuropean respiratory review","title":[{"title_sort":"European respiratory review","title":"European respiratory review"}]}],"title":[{"title_sort":"Natural variability in the disease course of SSc-ILD","title":"Natural variability in the disease course of SSc-ILD","subtitle":"implications for treatment"}]} | ||
| SRT | |a VONKMADELONATURALVAR2420 | ||